You are here: Welcome to the MPKB » Welcome to the MPKB » Starting the Marshall Protocol » Working with your physician » Helping a concerned physician to become comfortable with the MP
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:starting:physician:reluctant [06.01.2019] – [Specific research] sallieqhome:starting:physician:reluctant [06.01.2019] – [Specific research] sallieq
Line 211: Line 211:
 6 mg/kg olmesartan reduces the inflammatory process and bone loss [in rats] (({{pubmed>long:23775504}} )) PMID 23775504 6 mg/kg olmesartan reduces the inflammatory process and bone loss [in rats] (({{pubmed>long:23775504}} )) PMID 23775504
  
-Olmesartan at a dose of 10 mg/kg prevented the mucosal damage and inflammation associated with 5-FU-induced OM, increasing granulation and tissue repair. [in hamsters] (({{pubmed>long:    30125396}}))+Olmesartan at a dose of 10 mg/kg prevented the mucosal damage and inflammation associated with 5-FU-induced OM, increasing granulation and tissue repair. [in hamsters] (({{pubmed>long:30125396}})) PMID 30125396
  
  
Line 286: Line 286:
 OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}}))  PMID 25275251 OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}}))  PMID 25275251
  
 +we investigated the effects of RNH-6270, an active metabolite of olmesartan, on TNF-α-induced human glomerular EC (HGEC) damage to clarify the renoprotective mechanisms of ARBs. Our findings suggested that olmesartan might have protective effects against TNF-α-induced glomerular EC dysfunction.(({{pubmed>long:    23052181}})) PMID 23052181
 +
 +We orally administered olmesartan 1, 3, and 10 mg/kg/day to rats with EAM for 3 weeks. The cardioprotection of olmesartan may be due to suppression of inflammatory cytokines dependent of the hemodynamic modifications.  (({{pubmed>long:15124927}}))  PMID 15124927
 +
 +AlphaTau1 receptor blockers, olmesartan and valsartan (10(-9)-10(-6) mol/L) showed a significant reduction on TNF-alpha-induced LDH and NAG release in human renal proximal tubular epithelial cells (({{pubmed>long:    18331441}})) PMID 18331441
 +
 +The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. (({{pubmed>long:21061834}})) PMID 21061834
 +
 +
 +These data added to our previous results further provide a mechanistic rationale for olmesartan's antioxidant/anti-inflammatory potential translation, in the long term, toward anti-atherosclerotic/anti-remodeling effects reported by clinical trials. (({{pubmed>long:26240115}})) PMID 26240115
 +
 +Olmesartan attenuated CTGF induction, reduced perivascular fibrosis and ameliorated cardiac dysfunction in a PO heart. Our results provide insight into the beneficial effects of olmesartan on PO hearts, independent of blood-pressure lowering. [in rat] (({{pubmed>long:20944640}}))  PMID 20944640
  
 Long term treatment Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint (({{pubmed>long:25001274}}))   PMID 25001274 Long term treatment Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint (({{pubmed>long:25001274}}))   PMID 25001274
home/starting/physician/reluctant.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.